Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

Regulatory T cells in intravesical BCG therapy for non-muscle invasive bladder cancer

Funder: Japan Society for the Promotion of Science

Funding period
JPY 5.1 M
USD 45 K
Funding amount
Abstract
We investigated the affection of regulatory T cells in recurrence of bladder cancer. From analysis of 105 cases of non-muscle invasive bladder cancer, patients with high Treg invasion in the tumor had high intravesical recurrence rate. Similar results were found in the group treated with intravesical BCG. Therefore, we considered that regulatory T cells may affect to recurrence and progression of bladder cancer. Next, to investigate how regulatory T cells work with intravesical BCG therapy for bladder cancer, we evaluated the change of regulatory T cells among intravesical BCG therapy using a rat bladder cancer model. Tregs in the peripheral blood tended to be higher in the intravesical BCG treatment group than in the control group. We continue the treatment experiment combined intravesical BCG and Treg-adsorbing hemodialysis.
Similar projects All >
Sorted by: Start Date
Project list item
Intravesical delivery of an Fc-enhanced CD40 agonist antibody for the treatment of bladder cancer

Bladder Cancer Advocacy Network to Jeffrey Ravetch, David Knorr

USD 300,000
2020 - 2022
Project list item
Epigenetic regulators of subtype plasticity in bladder cancer

Bladder Cancer Advocacy Network to John Robert Christin

USD 1,700
2020 - 2020
Project list item
Defining NRF2 induced tumor invasion in bladder cancer

Bladder Cancer Advocacy Network to Yuki Kita, William Youngkwan Kim, Bernard Weissman

USD 50,000
2020 - 2021
Project list item
Alpha1H: A Unique Bladder Cancer Therapeutic, Acting with Great Precision

European Commission

USD 2,452,885
2020 - 2022
Project list item
Dissecting myeloid cell-mediated resistance to immune checkpoint blockade in bladder cancer

National Cancer Institute to NINA BHARDWAJ, JUN ZHU, MATTHEW GALSKY

USD 703,400
2020 - 2025

System

Categories
  • FOR (ANZSRC)

    1112 Oncology and Carcinogenesis

  • RCDC

    Cancer

  • RCDC

    Urologic Diseases

  • HRCS HC

    Cancer

  • Health Research Areas

    Biomedical

  • Broad Research Areas

    Clinical Medicine and Science